CRPC (M1c Visceral) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About CRPC (M1c Visceral)
Castration-Resistant Prostate Cancer (CRPC) M1c visceral is an aggressive form of prostate cancer that has spread to organs beyond the bones. This advanced diagnosis can bring significant challenges, both medically and financially. TheDrugClub is dedicated to easing the burden of medication costs, ensuring patients can access vital treatments without added stress.
What is CRPC M1c Visceral?
Castration-Resistant Prostate Cancer (CRPC) refers to prostate cancer that continues to progress despite hormone therapy aimed at lowering testosterone levels. It means the cancer has found ways to grow even when testosterone is suppressed. The 'M1c visceral' classification further defines this advanced stage, indicating that the cancer has metastasized (spread) to visceral organs – internal organs like the liver, lungs, or brain – rather than just bones or lymph nodes. This is a more aggressive form of CRPC and often presents unique treatment challenges.
Understanding the Diagnosis
When prostate cancer spreads to visceral organs, it signifies a more advanced and serious stage of the disease. Symptoms can vary depending on the organs affected, but might include pain, fatigue, weight loss, or difficulty breathing. Diagnosis typically involves imaging tests like CT scans, MRIs, and PET scans, in addition to blood tests for PSA levels and other markers.
Common Treatments and Medications
Treating CRPC M1c visceral often involves a multi-faceted approach aimed at controlling the cancer's growth, managing symptoms, and improving quality of life. Due to the aggressive nature of visceral metastasis, treatment plans are often tailored to the individual and may include:
- Androgen Receptor-Targeted Therapies: Medications like enzalutamide (Xtandi) and abiraterone acetate (Zytiga) continue to be vital, even in CRPC, by further disrupting androgen pathways.
*
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.